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Ra-223 or placebo respectively. Patients entered the model progression-free, 
receiving active treatment until progression or completion of the therapy course. 
Health states reflected patients experiencing first or subsequent SRE. In the trial, 
SRE was defined as treatment with external-beam radiation therapy (EBRT), 
surgical intervention, occurrence of pathological bone fracture, or spinal cord 
compression. A 5-year time horizon was considered. Costs were estimated from 
a US payer perspective. SRE costs were obtained by multiplying the number  
of patients experiencing SRE by its specific treatment cost (including 
hospitalization costs). RESULTS: Ra-223 increased mean life expectancy by 0.325 
(95% CI: 0.324-0.326) years in the ITT population and 0.517 (95% CI: 0.516-0.518) 
years in the subgroup of patients who had not received first-line docetaxel.  
Ra-223 was projected to lead to 44% reduction in the cost of treatment of SREs 
versus BSC: 46% reduction in pathologic bone fracture costs; 48% for spinal  
cord compression; 16% for external beam radiation; and 11% for  
surgical interventions. A total of 32.9% of patients suffered a first SRE for Ra-223 
versus 37.8% for placebo and 6.5% and 7.8%, respectively, suffered two or more 
SRE events. CONCLUSIONS: In patients treated with BSoC, Ra-223 reduced  
costs of SREs. Future studies will evaluate the total cost of care related to  
the benefit of Ra-223 versus placebo in patients treated with BSoC in  
mCRPC once the cost of therapy and the impact on quality adjusted survival are 
known.  
 
PCN36  
COST ANALYSIS MODEL BETWEEN THE COBAS BRAF TEST AND SANGER 
SEQUENCING WHEN TREATING MALIGNANT MELANOMA BASED ON THE 
PRESENCE OF V600 MUTATIONS  
Poulios N1, Pinto L1, Carlton R2, Bramley T2, Tierney R3, Palma JF1 
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA, 
3Matrix Knowledge, London, UK  
OBJECTIVES: Validated companion diagnostic assays permit collection of critical 
clinical data that leads to actionable treatment decisions and better patient 
outcomes. The cobas BRAF test is an FDA-approved companion diagnostic that 
identifies V600 mutation positive malignant melanoma to determine patient 
eligibility for treatment with vemurafenib. Sanger sequencing is also a validated, 
lab developed test that provides similar information for the gene encoding the 
BRAF protein. Test performance differences can have an impact on patient 
outcomes and overall cost of testing and treatment. METHODS: Based on assay 
performance data for both tests, generated during the phase 2 BRIM-2 (N=132), 
BRIM-2/3 (N=433) and phase 3 BRIM-3 (N=449) studies, an integrated drug-
diagnostic budget impact model was developed from a third-party payer 
perspective assuming a 6-month treatment period. Cost estimates were based on 
testing 100% unresectable stage III-IV melanomas assuming 50% incidence of 
BRAF mutations. Diagnostic costs were based on reimbursement for average 
code-stacks across various lab and therapeutic costs for vemurafenib (and 
ipilimumab) were inclusive of administrative and adverse event costs. Sensitivity 
models were run to estimate costs across a wide range of values for the various 
model parameters. RESULTS: Overall, the sum of invalid tests, false positive and 
false negative results across all 3 studies was 14.6% (148/1014) for Sanger 
sequencing and 0.6% (6/1014) for the cobas BRAF test. Use of the cobas BRAF test 
versus Sanger sequencing resulted in total saving of $14.2 million or $1,479.17 
per patient in the BRIM-3 study and $21.9 million or $2,281.25 per patient in the 
BRIM2/3 dataset. Savings were primarily a result of avoiding unnecessary or 
inappropriate drug therapy and diagnostic costs accounted for a small fraction 
(0.13-0.29%) of total expenditures. CONCLUSIONS: Use of the clinically validated 
and more accurate cobas BRAF test resulted in significant cost savings relative to 
Sanger sequencing for BRAF mutations.  
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OBJECTIVES: Ifosfamide, a key chemotherapy for advanced stages of the  
rare cancer soft-tissue sarcoma (STS), is a generic medication. However, 
administration often entails hospitalization and adjuvant mesna as prophylaxis 
against hemorrhagic cystitis; resultant costs are unknown. This study examined 
health care costs and its drivers for managed care patients with STS who were 
treated with ifosfamide and other chemotherapies. METHODS: We 
retrospectively studied administrative claims of adult STS patients in a large US 
managed care plan who initiated chemotherapy between 2000−2011. The first 
chemotherapy treatment following diagnosis identified in medical claims was 
categorized by setting of chemotherapy initiation (ambulatory or hospital). 
Health care utilization and costs were identified over a 1-year follow-up 
(retaining patients dying prior to 1 year); patient/clinical characteristics were 
assessed over a 6-month baseline. Analyses included descriptive statistics and 
ordinary least squares on logged costs adjusted for patient/clinical 
characteristics (retransformed with smearing estimator). RESULTS: Ifosfamide-
treated patients (alone, n=18, or combined with doxorubicin, n=47) were younger 
compared to the 149 patients in 4 other chemotherapy cohorts: means 50-52, 
versus 58 years for the next youngest (doxorubicin, gemcitabine+docetaxel 
cohorts), p=0.004. Total health care costs were significantly higher for ifosfamide 
cohorts (adjusted means $ 115,559 and $ 129,537) versus other cohorts except for 
gemcitabine+docetaxel (means ranged from $73,496 to $117,451, p<0.05). 
Differences in medical costs were due to higher ambulatory and inpatient 
expenditures for ifosfamide cohorts, which generally had higher numbers of 
visits including inpatient visits: ifosfamide means 0.94, 1.49, versus other cohorts 
0.65, 0.72, 0.81, and 1.51 (gemcitabine+docetaxel), p<0.016. CONCLUSIONS: 
Patients with STS treated with ifosfamide had significantly higher health care 
costs than did patients treated with most other chemotherapies, suggesting that 
although a generic medication, ifosfamide may impose a higher disease 
management burden and impact on health plan budgets. Whether emerging 
therapies will result in lower health care costs warrants exploration.  
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OBJECTIVES: Incidence of hepatocellular carcinoma (HCC) is increasing in the 
U.S. and worldwide. Several treatments are available for patients newly 
diagnosed with the disease. We examine cumulative Medicare-paid expenditures 
and survival associated with various treatment modalities for HCC in a 
population for which it is most treated. METHODS: Medicare enrollees with an 
initial diagnosis of primary HCC between 2000-2007 were followed through 2009. 
Data are from SEER and linked Medicare databases, with claims generated from 
Parts A and B. Multivariate Cox proportional hazards models were used to 
estimate risk and calculate mean all-cause/HCC-related survival associated with 
transplant, resection, liver directed therapy, radiation, systemic chemotherapy 
or no treatment. Partitioned inverse probability-weighted least squares 
regression estimated cumulative Medicare expenditures adjusted for censoring 
and covariates. Bootstrapping was used to obtain 95% Confidence Intervals for 
cost estimates. RESULTS: Cancer stages one, two, three and four represented 
24%, 9%, 14%, and 17% of the 11,047 patients, respectively. Nearly one-third (37%) 
were unstaged, 66% were male, 75% Caucasian, 10% African American; 60% of 
patients were untreated, 16% liver directed, 8% chemotherapy, 8% resection, 4% 
radiation, and 4% transplant. Using all-cause (HCC-related) mortality, transplant 
patients incurred an average $263,296 [95%CI: $244,200-$282,392] over an average 
5.47 (6.9) years, resection $131,812 [$126,770-$136,854] over 3.5 (5.1) years, liver 
directed $91,488 [$88,749-$94,227] over 2.2 (3.8) years, chemotherapy $55,379 
[$53,442-$57,316]over 1.2 (2.8) years, radiation $58,308 [$55,355-$61,261] over 1.2 
(2.6) years, and no treatment $27,937 [$27,355-$28,519] over 0.6 (1.1) years. 
CONCLUSIONS: Cumulative Medicare expenditures were over 9x higher for 
transplant versus no treatment, nearly 5x for resection, over 3x for liver directed, 
and nearly double for chemotherapy or radiation, even after adjusting for cancer 
stage and other confounders. Differences in Medicare spending between 
treatment modalities were nearly proportional to differences in (all-cause) years 
survived after HCC diagnosis.  
 
PCN39  
REAL-WORLD DATA ANALYSIS OF COLORECTAL CANCER (CRC) TREATMENT 
WITH BIOLOGIC DRUGS IN A MEDICAL COOPERATIVE IN BRAZIL  
Santos MCL, Maturana MS 
Unimed São José do Rio Preto, São José do Rio Preto, Brazil  
OBJECTIVES: Colorectal cancer is the third highest incidence amongst all cancers 
worldwide. Biologics are increasingly used as a treatment option, and due to 
high associated drug cost HMOs need to minimize expenditures by choosing less 
costly treatment strategies. Real-world data is growing in importance in health 
care decision making especially in coverage and reimbursement decisions. 
Therefore, the objective of the study is support treatment decision making by 
providing evidence based on real-world data, focusing on most used biologics in 
metastatic CRC: bevacizumab and cetuximab. METHODS: A review of 
administrative claims database of Unimed São José do Rio Preto (medical 
cooperative responsible for 118,000 lives in São Paulo-Brazil) was conducted for 
patients who underwent CRC treatment between December 2009 through 
January 2012. In order not to disclose confidential commercial arrangements 
with suppliers analysis were focused on total costs of treatment (drugs, 
devices/materials and room taxes). In the cases where a single patient 
underwent treatment with more than one biologic the analysis was performed 
considering the different regimens for the patient, obtaining daily 
costs/regimen/patient, and then converted on monthly basis. Focus was given to 
costs related to bevacizumab plus chemotherapy (Bev+CT) and cetuximab plus 
chemotherapy (Cet+CT) regimens. Also, regimens were classified into irinotecan 
or oxaliplatin-based. Costs were reported in Brazilian Reais (BRL1.00~USD0.48 
December 2012). RESULTS: A total of 108 CRC patients were identified and 
regimens were 22.7% Bev+CT and 16.3% Cet+CT. Approximately 80% of both 
biological drugs were combined with irinotecan-based schemes. Average 
cost/patient/month were BRL 12,585 (SD: BRL3,588) for Bev+CT and BRL 17,178 
(SD: BRL3,797) for Cet+CT. CONCLUSIONS: Results indicate potential resource 
savings favoring bevacizumab. If all patients treated with cetuximab were 
treated with bevacizumab instead, it could averagely result in savings of BRL 
64,301 per month (less 26.7%). Study had limitation regarding identification of 
treatment line and sample size precluded identification of statistical difference 
between treatments.  
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OBJECTIVES: Abiraterone acetate (AA), a selective androgen biosynthesis 
inhibitor, blocks the action of CYP17, thereby inhibiting adrenal and intratumoral 
